Tibet Zhongweikang Investment Management Co., Ltd. entered into an agreement to acquire Beijing Zhongwei Xinkang Gene Biotechnology Co., Ltd. from Tibet Weixinkang Medicine Co., Ltd. (SHSE:603676) for CNY 35.3 million on March 15, 2018. For the year ended December 31, 2017, Beijing Zhongwei Xinkang Gene Biotechnology Co., Ltd. reported total assets of CNY 18.6 million, net assets of CNY 18.6 million, revenue of CNY 0, and net loss of CNY 1.1 million. The transaction is subject to the shareholders’ approval of Tibet Weixinkang Medicine Co., Ltd. The transaction has been approved in the 16th meeting of the 1st Directorate of Tibet Weixinkang Medicine Co., Ltd. on March 15, 2018. Tibet Zhongweikang Investment Management Co., Ltd. cancelled the acquisition of Beijing Zhongwei Xinkang Gene Biotechnology Co., Ltd. from Tibet Weixinkang Medicine Co., Ltd. (SHSE:603676) on March 15, 2019.